8GN Stock Overview
A pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cessatech A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 1.65 |
| 52 Week High | DKK 2.90 |
| 52 Week Low | DKK 0.69 |
| Beta | 0.57 |
| 1 Month Change | 16.74% |
| 3 Month Change | 21.93% |
| 1 Year Change | 121.24% |
| 3 Year Change | 65.93% |
| 5 Year Change | n/a |
| Change since IPO | -41.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8GN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.5% | -6.6% | 1.1% |
| 1Y | 121.2% | -25.3% | 16.0% |
Return vs Industry: 8GN exceeded the German Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: 8GN exceeded the German Market which returned 16% over the past year.
Price Volatility
| 8GN volatility | |
|---|---|
| 8GN Average Weekly Movement | 23.2% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 8GN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8GN's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Jes Trygved | www.cessatech.com |
Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel.
Cessatech A/S Fundamentals Summary
| 8GN fundamental statistics | |
|---|---|
| Market cap | €31.00m |
| Earnings (TTM) | -€2.18m |
| Revenue (TTM) | €166.53k |
Is 8GN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8GN income statement (TTM) | |
|---|---|
| Revenue | DKK 1.24m |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 1.24m |
| Other Expenses | DKK 17.50m |
| Earnings | -DKK 16.25m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,307.72% |
| Debt/Equity Ratio | 0% |
How did 8GN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 23:20 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cessatech A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.